PNT News and Press, POINT Biopharma Global Inc. From 03/27/23

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023 INDIANA...

INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical tr...

Summary POINT Biopharma Global Inc. has a set of radioligand therapies in various stages. It has a major deal with Lantheus. The company has a long cash runway. POINT Biopharma Global Inc. ( PNT ) is a clinical-stage company developing radioligands targeting cancer. It...

INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced the completion of enrollmen...

INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino a...

Combining 177 Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model 177 Lu-PNT6555 , the lead of the PNT2004 pan-canc...

POINT Biopharma Global press release ( NASDAQ: PNT ): Q3 GAAP EPS of -$0.26 beats by $0.01 . Cash, Cash Equivalents and Investments as of September 30, 2022,  $291.5 million For further details see: POINT Biopharma Global GAAP EPS of -$0.26 beats by $0.0...

INDIANAPOLIS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for...

Collaboration pairs POINT’s expertise in next generation radioligand development and manufacturing with Lantheus’ commercial leadership in PSMA PET and radiopharmaceuticals Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding cer...

PNT2001 displays enhanced internalization, biodistribution, and pre-clinical efficacy in multiple tumor models, making it a prime candidate for the delivery of actinium-225 Targeting IND/CTA submission for PNT2001 program in H1 2023 INDIANAPOLIS, Oct. 17, 2022 (GLOBE NEWSW...